BTN1A1, a member of the butyrophilin lineage, represents an intriguing therapeutic target for diverse immune disorders. The ICT-01-N297A agent, specifically designed to bind BTN1A1, offers a distinct approach https://www.targetmol.com/compound/ict_01_n297a